Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34 positive cells
- Development stage
- Unknown
- Lead developer
- Lisata Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous CD34 positive cells are a population of hematopoietic stem and progenitor cells (HSPCs) derived from the patient's own body, typically harvested from peripheral blood following mobilization with agents like granulocyte colony-stimulating factor (G-CSF). These cells are defined by the expression of the CD34 surface glycoprotein, a marker for primitive hematopoietic cells. In regenerative medicine, autologous CD34+ cells are investigated for their ability to home to sites of injury and promote tissue repair through paracrine signaling, angiogenesis, and potential differentiation into various cell lineages. Clinical applications include the treatment of ischemic stroke, where they are administered intrathecally to enhance neurological recovery, as well as in cardiovascular and peripheral vascular diseases.
- Other names
- autologous CD34+ cellsautologous CD34-positive cellsautologous CD34+ hematopoietic stem cells
Beyond the preview
Go deeper on autologous CD34 positive cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34 positive cells.